Albany, NY -- (SBWIRE) -- 11/18/2016 -- Rubella or German measles is a serious condition (disease) caused by the infection of rubivirus (genus). Sometimes rubella when passed from pregnant mother to her baby then it is termed as congenital rubella. Rubella is a contagious disease and can spread through air or close contact between patient and a healthy individual. Signs and symptom of rubella include fever, headache, inflammation of the eyes and muscle or joint pain.

Culture test (nasal or throat swab culture) and blood test to check the function of immune system are the major tests performed for the detection of rubella. Women who are pregnant must undergo rubella test to know the functioning of immune system against rubella virus. There remains chance of miscarriage or stillbirth for those pregnant mothers who are suffering from measles as the child may be born with birth defects.

Download exclusive Sample of this report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2935

Presently there is no treatment option available in the market for the treatment of rubella. Patients are prescribed acetaminophen for reduction of rubella fever. Rubella can be prevented with the utilization of measles-mumps-rubella (MMR) vaccine. Rubella vaccine is recommended for all children and is routinely given when children are 12 months to 15 months old. Almost everyone who receives the vaccine has immunity to rubella for his lifetime.

Rubella Testing Market: Segmentation

The global market for rubella testing can be segmented as:

By Application
Hospitals
Commercial/Private labs
Physician offices
Public health labs

Rubella Testing Market: Drivers

The global market for rubella testing is being driven primarily due to increasing awareness among people and advancement in diagnostic test. Moreover, government initiatives and support also accounted for the growth of the global rubella testing market. Pregnant mother who are suffering from rubella and are unaware about the high risk of passing the disease from her to unborn baby also contributes significantly in the market growth.

Centre for Disease Control and Prevention (CDC) stated that more than 100,000 infants are born with congenital rubella syndrome (CRS) annually worldwide. World Health Organization (WHO) revealed that in 1996, the number of countries that have incorporated rubella-containing vaccines into their routine national immunization program was 83. Later in 2011, the number was increased to 130 for the incorporation of rubella-containing vaccines into their routine national immunization.

View exclusive Global strategic Business report:
http://www.transparencymarketresearch.com/rubella-diagnostic-testing-market.html

Rubella Testing Market: Region-wise Outlook

North America dominates the global market for rubella testing due to strong demand of diagnostic test in this region. Moreover increasing awareness among people and initiative taken by the federal government also accounted for the market growth in North American region. Europe represents the second position in the global rubella testing market due to increasing awareness among people and extensive government initiative taken by the European government. For an instance, in October 2010, WHO Region of the America and Europe has established rubella elimination and CRS prevention goals for the year 2010 and 2015.

Asia - Pacific is considered as an untapped market due to lack of awareness among people about rubella testing. Asian market growth will be fuelled by the presence of untapped opportunities due to extensive increase in the healthcare infrastructure and growing market penetration in this region.

Rubella Testing Market: Key Players

Major market players contributing in the global market share of rubella testing market includes Abbott Laboratories, Inc., Becton, Dickinson and Company, Biomerica, Inc., bioMerieux, Inc., Novartis Diagnostics, Johnson & Johnson Diagnostics, Inc., Olympus Corporation, Qiagen N.V., Siemens AG, Thermo Fischer Scientific, Inc., and Zenith Healthcare Ltd.